| Literature DB >> 15043396 |
Bernhard A Haslinger1, Gabriele Arendt.
Abstract
TMC-125, a non-nucleoside reverse transcriptase inhibitor, is being developed by Tibotec for the potential treatment of HIV infection. Phase IIa trials in treatment-naive and treatment-experienced HIV-1-infected individuals had been completed by February 2002. A long-term, phase IIb, dose-finding study in treatment-experienced patients started enroling patients in a number of European countries during 2002, and Canada during 2003.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15043396
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472